These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 31608801)

  • 1. Dry powder inhalers: upcoming platform technologies for formulation development.
    Mehta PP
    Ther Deliv; 2019 Sep; 10(9):551-554. PubMed ID: 31608801
    [No Abstract]   [Full Text] [Related]  

  • 2. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
    Rawal T; Kremer L; Halloum I; Butani S
    J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Powder Production and Particle Engineering for Dry Powder Inhaler Formulations.
    Lin YW; Wong J; Qu L; Chan HK; Zhou QT
    Curr Pharm Des; 2015; 21(27):3902-16. PubMed ID: 26290193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spray-Dried PulmoSphere™ Formulations for Inhalation Comprising Crystalline Drug Particles.
    Weers JG; Miller DP; Tarara TE
    AAPS PharmSciTech; 2019 Feb; 20(3):103. PubMed ID: 30734187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in device and formulation technologies for pulmonary drug delivery.
    Chan JG; Wong J; Zhou QT; Leung SS; Chan HK
    AAPS PharmSciTech; 2014 Aug; 15(4):882-97. PubMed ID: 24728868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry powder inhalation: past, present and future.
    de Boer AH; Hagedoorn P; Hoppentocht M; Buttini F; Grasmeijer F; Frijlink HW
    Expert Opin Drug Deliv; 2017 Apr; 14(4):499-512. PubMed ID: 27534768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technological and practical challenges of dry powder inhalers and formulations.
    Hoppentocht M; Hagedoorn P; Frijlink HW; de Boer AH
    Adv Drug Deliv Rev; 2014 Aug; 75():18-31. PubMed ID: 24735675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dry powder inhalable formulations for anti-tubercular therapy.
    Parumasivam T; Chang RY; Abdelghany S; Ye TT; Britton WJ; Chan HK
    Adv Drug Deliv Rev; 2016 Jul; 102():83-101. PubMed ID: 27212477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation Design of Dry Powders for Inhalation.
    Weers JG; Miller DP
    J Pharm Sci; 2015 Oct; 104(10):3259-88. PubMed ID: 26296055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic Comparison of a Unit Dose Dry Powder Inhaler with a Multidose Dry Powder Inhaler for Delivery of Fluticasone Furoate.
    Mehta R; Moore A; Riddell K; Joshi S; Chan R
    J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):332-338. PubMed ID: 28463040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose dry powder inhalers to overcome the challenges of tuberculosis treatment.
    Momin MAM; Tucker IG; Das SC
    Int J Pharm; 2018 Oct; 550(1-2):398-417. PubMed ID: 30179703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary delivery of inhalable nanoparticles: dry powder inhalers.
    Al-Hallak MH; Sarfraz MK; Azarmi S; Roa WH; Finlay WH; Löbenberg R
    Ther Deliv; 2011 Oct; 2(10):1313-24. PubMed ID: 22826885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
    Muralidharan P; Hayes D; Mansour HM
    Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose emission characteristics of placebo PulmoSphere® particles are unaffected by a subject's inhalation maneuver.
    Weers J; Ung K; Le J; Rao N; Ament B; Axford G; Maltz D; Chan L
    J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):56-68. PubMed ID: 22691109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation techniques for high dose dry powders.
    Brunaugh AD; Smyth HDC
    Int J Pharm; 2018 Aug; 547(1-2):489-498. PubMed ID: 29778822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How can we bring high drug doses to the lung?
    Claus S; Weiler C; Schiewe J; Friess W
    Eur J Pharm Biopharm; 2014 Jan; 86(1):1-6. PubMed ID: 24300444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery Technologies for Orally Inhaled Products: an Update.
    Moon C; Smyth HDC; Watts AB; Williams RO
    AAPS PharmSciTech; 2019 Feb; 20(3):117. PubMed ID: 30783904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
    Lau M; Young PM; Traini D
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.